Kairos Pharma Ltd. Reports Positive Safety Results in Phase 2 Study of Prostate Cancer Drug ENV-105

Kairos Pharma Ltd. (NYSE American: KAPA) has reported encouraging interim safety results from its ongoing Phase 2 trial of ENV-105 (carotuximab) in patients with metastatic castration-resistant prostate cancer. The study, involving the first ten patients, revealed no dose-limiting toxicities or unexpected adverse events, with ENV-105 being well tolerated in combination with apalutamide, a standard hormone therapy. This development is crucial as it underscores the potential of ENV-105, a first-in-class CD105 antagonist, to offer a safer treatment option for a challenging cancer type.

The trial, which is being conducted at prestigious institutions including Cedars-Sinai, City of Hope, and Huntsman Cancer Center, aims to enroll 100 patients, with interim efficacy data anticipated by September 2025. The positive safety profile observed so far paves the way for Kairos Pharma to engage with regulators regarding a potential Phase 3 study, highlighting the drug's promise in addressing significant unmet medical needs in oncology.

For more details on the trial and Kairos Pharma's innovative approach to overcoming drug resistance in cancer, visit https://ibn.fm/S1b3a.